These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23268906)

  • 21. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE; Kim YC
    Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome].
    Suto T; Ishiyama K; Yabuki H; Mori N; Inoue K; Chiba M; Igawa A; Watanabe T; Fujimoto H; Suzuki Y; Sugawara M; Saito T; Kobayashi Y; Matsuda M; Ikeda E; Sato T; Iizawa H
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1729-33. PubMed ID: 20841936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
    Marsé H; Van Cutsem E; Grothey A; Valverde S
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S16-30. PubMed ID: 15341879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
    Son HS; Lee WY; Lee WS; Yun SH; Chun HK
    Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
    Disel U; Gürkut O; Abali H; Kaleağasi H; Mertsoylu H; Ozyilkan O; Saif MW
    Cutan Ocul Toxicol; 2010 Jun; 29(2):140-2. PubMed ID: 20298142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hand-foot syndrome induced by chemotherapy: a case study].
    Simão DA; Lima ED; Souza RS; Faria TV; Azevedo GF
    Rev Bras Enferm; 2012; 65(2):374-8. PubMed ID: 22911424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
    Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
    Scheithauer W; Blum J
    Oncology (Williston Park); 2004 Aug; 18(9):1161-8, 1173; discussion 1173-6, 1181-4. PubMed ID: 15471200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adjuvant chemotherapy with capecitabine for colon cancer - a case series].
    Kuji M; Masuko H; Yamagami H; Matsumoto S; Tanioka T; Takahashi S; Ishizu H; Takahashi M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1752-4. PubMed ID: 25731318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapy traces on hands and feet in a patient with colon cancer].
    Stiefelhagen P
    MMW Fortschr Med; 2012 Jun; O 154 Suppl 2():9. PubMed ID: 22916416
    [No Abstract]   [Full Text] [Related]  

  • 32. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
    Saif MW; Elfiky A; Diasio R
    Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical henna for capecitabine induced hand-foot syndrome.
    Yucel I; Guzin G
    Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.
    Paule I; Tod M; Hénin E; You B; Freyer G; Girard P
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):447-55. PubMed ID: 21809035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
    Lee SD; Kim HJ; Hwang SJ; Kim YJ; Nam SH; Kim BS
    Korean J Intern Med; 2007 Jun; 22(2):109-12. PubMed ID: 17616027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
    Wang Y; Yang H; Wei JF; Meng L
    Curr Med Res Opin; 2012 Dec; 28(12):1911-9. PubMed ID: 23145857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High frequency of hand foot syndrome with capecitabine.
    Kamil M; Haron M; Yosuff N; Khalid I; Azman N
    J Coll Physicians Surg Pak; 2010 Jun; 20(6):421-2. PubMed ID: 20642979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
    Law CC; Fu YT; Chau KK; Choy TS; So PF; Wong KH
    Dis Colon Rectum; 2007 Dec; 50(12):2180-7. PubMed ID: 17963003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
    Kara IO; Sahin B; Erkisi M
    Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Aprile G; Mazzer M; Moroso S; Puglisi F
    Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.